Vettenranta K
1Division of Hematology-Oncology and Stem Cell Transplantation, Hospital for Children and Adolescents, University of Helsinki, Helsinki, Finland.
Bone Marrow Transplant. 2008 Jun;41 Suppl 2:S14-7. doi: 10.1038/bmt.2008.47.
Myeloablative conditioning continues to be employed in hematopoietic stem cell transplantation among patients with pediatric transplant indications. Fractionated TBI (fTBI) remains, with its considerable anti-leukemic potential, the cornerstone of conditioning in the most common of pediatric indications, ALL in its first, second or subsequent remission despite its well-established long-term sequelae. The feasibility of chemotherapy-only regimens has been established and these regimens widely employed in other pediatric indications, for example, in ALL below the age of 2 years, AML, myelodysplasias or severe aplastic anemia. Conditioning regimens are being modified with data accumulating on the role of, for example, pre-transplant residual disease, advanced HLA-typing or haploidentical transplantations in the pediatric setting.
清髓性预处理在有儿科移植指征的患者的造血干细胞移植中仍被采用。分次全身照射(fTBI)因其相当大的抗白血病潜力,仍是最常见儿科指征(即处于首次、第二次或后续缓解期的急性淋巴细胞白血病(ALL))预处理的基石,尽管其长期后遗症已得到充分证实。仅化疗方案的可行性已得到确立,并且这些方案在其他儿科指征中广泛应用,例如,年龄在2岁以下的ALL、急性髓系白血病(AML)、骨髓增生异常综合征或重型再生障碍性贫血。随着例如移植前残留疾病、高级别HLA分型或儿科环境中单倍体相合移植的作用等数据的积累,预处理方案正在不断修改。